22nd Century Group Expanded Non-GMO Tobacco Platform
The company adjusted its nicotine-reduction technology to meet European regulatory standards as agencies consider new limits.
Updated on Sept. 28, 2026 in Biotech
Live Poll
Should governments mandate lower nicotine levels in all combustible tobacco products?
22nd Century Group has expanded its plant-science platform to produce reduced-nicotine tobacco without genetic modification. This follows a December 2025 recommendation by the French health agency ANSES to set a maximum nicotine limit for all combustible tobacco products.
Why it matters
The company developed the non-GMO process to navigate strict EU regulations on genetically modified organisms while aligning with emerging public health frameworks that target smoking addiction. Regulatory proposals for a new EU tobacco control framework are expected by the end of 2026.
22nd Century Group utilizes patented technology to regulate alkaloid biosynthesis in plants, achieving a 95% reduction in nicotine. The company estimates this shift could support a sustainable legal market of €8-13 billion over three to five years.
The players
22nd Century Group
A biotech company that specializes in plant science and tobacco harm reduction through its proprietary alkaloid biosynthesis regulation technology.
ANSES
The French Agency for Food, Environmental and Occupational Health and Safety, which provides expert scientific assessments for public health policy.
FDA
The U.S. Food and Drug Administration, which oversees the authorization of tobacco products and the evaluation of modified-risk designations.
The details
The firm regulates alkaloid biosynthesis—the biological process by which plants produce chemical compounds—to limit nicotine levels in its tobacco plants. By transitioning to a non-GMO approach, the company avoids restrictions on genetically modified organisms (GMOs—living organisms whose genetic material has been altered). This technology builds upon existing research, including the company's Spectrum cigarettes supplied to U.S. agencies since 2011.
Timeline
2011: The company began supplying Spectrum research cigarettes to U.S. agencies.
December 2019: The FDA authorized the VLN cigarette product line.
December 2021: The FDA granted the first Modified Risk Tobacco Product designation.
December 5, 2025: ANSES validated its report on nicotine reduction.
May 2026: The FDA filed company MRTP renewal applications for review.
The Tech Race
This move positions 22nd Century Group to capture market share within the shifting landscape of global tobacco regulation. It follows the trajectory of the European Commission's tobacco control framework, which is currently evaluating evidence that may force the industry toward lower-nicotine standards.
The availability of these products depends on the formal adoption of nicotine-reduction laws across European member states. Once implemented, these standards would likely phase out high-nicotine combustible cigarettes in favor of reduced-nicotine alternatives for adult smokers.
The takeaway
The move suggests a shift toward mandatory nicotine ceilings in European markets. Observers should track the European Commission's legislative proposals due by the end of 2026 to see if these market-based reductions become mandatory compliance standards.
What happens next
Legislative proposals for the new EU tobacco control framework are expected before the end of 2026.
Further reading
For more information on the latest advancements in this sector, visit Biotech.
Live Poll
Should governments mandate lower nicotine levels in all combustible tobacco products?
